14-day Premium Trial Subscription Try For FreeTry Free
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
AQR Capital Management LLC cut its stake in shares of Pacira Biosciences Inc (NASDAQ:PCRX) by 75.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and E
Mason Street Advisors LLC raised its position in Pacira Biosciences Inc (NASDAQ:PCRX) by 2.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and
Amid the coronavirus stock market crash, Delaware Funds' Alex Ely seeks stocks that benefit from the crisis.
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pfizer (PFE) and Seattle Genetics (SGEN) with bullish
Goldman Sachs Group Inc. raised its position in shares of Pacira Biosciences Inc (NASDAQ:PCRX) by 9.3% in the fourth quarter, according to the company in its most recent filing with the Securities & E
RBC Capital analyst Randall Stanicky maintained a Hold rating on Endo International (ENDP) today and set a price target of $6.00. The company's shares
RBC Capital analyst Randall Stanicky maintained a Hold rating on Endo International ( ENDP – Research Report ) today and set a price target of $6.00 . The company’s shares closed last Thursday at
In a report issued on March 29, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Principia Biopharma (PRNB), with a price target of $76.00.
In a report issued on March 29, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Principia Biopharma ( PRNB – Research Report ), with a price target of $76.00 . The company’s shares c
RBC Capital analyst Randall Stanicky maintained a Hold rating on Teva Pharmaceutical Industries (TEVA) today and set a price target of $11.00. The
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE